Background: Lanadelumab is the only long-term prophylaxis indicated for reduced administration frequency in patients with hereditary angioedema who have been well controlled for > 6 months. Understanding the characteristics of patients who reduce administration frequency will help identify populations where frequency modifications may be appropriate.
Objective: We aimed to describe characteristics of patients who did and did not reduce lanadelumab administration frequency to inform real-world dosing regimens, and characteristics indicative of sustained frequency reduction.
Background: Hereditary angioedema (HAE) is a rare disorder in which unpredictable angioedema attacks significantly impact patient quality of life (QoL). There is limited information regarding patient experiences and perspectives of HAE management within underrepresented racial and ethnic groups.
Objective: To gain insight into the experiences and perspectives of medical care and treatment for HAE among underrepresented racial and ethnic groups in the US.
Objective: This scoping review will aim to determine the methodological rigor and quality of out-of-hospital clinical practice guidelines (CPGs) by collating and describing all literature that assessed these documents using a structured appraisal instrument.
Introduction: In the out-of-hospital setting, the provision of emergency health care by paramedics and first responders is guided, directed, or informed by localized, overarching CPGs. Numerous CPGs in this setting have been assessed for their methodological rigor and overall quality using an appraisal instrument.
Galeazzi-equivalent fracture is a very rare type of fracture. Unlike the "classic" adult form of Galeazzi fracture, where the distal radioulnar joint (DRUJ) is dislocated and the triangular fibrocartilage complex (TFCC) is often damaged, the DRUJ and TFCC may remain intact in children. In this article, we report the case of an 11-year-old boy with a Galeazzi-equivalent fracture.
View Article and Find Full Text PDFIntroduction: Diazoxide is the first-line treatment for children with hyperinsulinemic hypoglycemia (HI). In these cases, diazoxide raises blood glucose levels by suppressing insulin release, preventing hypoglycemia, and potentially devastating end-organ sequelae. Hyperosmolar hyperglycemic state (HHS) is an exceedingly rare side effect of diazoxide.
View Article and Find Full Text PDF